bioMerieux (OTCMKTS:BMXMF) Given Average Recommendation of “Reduce” by Brokerages

Shares of bioMerieux (OTCMKTS:BMXMF) have received an average recommendation of “Reduce” from the six ratings firms that are currently covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a sell rating and four have assigned a hold rating to the company.

BMXMF has been the topic of a number of recent research reports. Deutsche Bank Aktiengesellschaft reissued a “hold” rating on shares of bioMerieux in a research report on Wednesday, June 17th. UBS Group cut shares of bioMerieux from a “buy” rating to a “neutral” rating in a research note on Monday, June 1st. Morgan Stanley lowered shares of bioMerieux from an “overweight” rating to an “underweight” rating in a research report on Tuesday, June 23rd. Zacks Research cut shares of bioMerieux from a “hold” rating to a “strong sell” rating in a report on Friday, July 31st. Finally, Piper Sandler initiated coverage on shares of bioMerieux in a research report on Thursday, June 11th. They issued a “neutral” rating for the company.

bioMerieux Stock Performance

BMXMF opened at $78.99 on Wednesday. The business’s 50-day moving average price is $79.97 and its two-hundred day moving average price is $95.49. bioMerieux has a 1 year low of $77.00 and a 1 year high of $152.00. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.39 and a quick ratio of 1.48.

About bioMerieux

bioMérieux is a global leader in in vitro diagnostics, specializing in the development, manufacture and distribution of diagnostic solutions that determine the source of disease and contamination to improve patient health and ensure consumer safety. The company’s product portfolio encompasses a broad range of assays and instruments for microbiological and immunoassay testing, including molecular diagnostics for infectious diseases, immunoassays for autoimmune and oncology markers, and traditional microbial identification and antimicrobial susceptibility testing.